Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 14
Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 15
Atopix Acquires OC459 and CRTH2 Antagonists from Oxagen 17
Venture Financing 19
Atopix Therapeutics Raises Additional Funds through Venture Financing 19
Atopix Therapeutics Raises Funds through Extended Series A Financing 20
Atopix Raises USD5.7 Million in Series A Financing Round 21
Private Equity 22
Charterhouse Capital Partners Acquires Doc Generici For US$424 Million 22
Partnerships 24
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 24
Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 25
Aptuit Enters into Agreement with Chiesi Farmaceutici 26
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 27
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici for Bronchitol in US 28
Chiesi Farmaceutici Enters into Agreement With University College London 29
Pharmathen Enters Into Co-Promotion Agreement With Chiesi For Nebulized Inhaled Corticosteroid 30
Activaero Enters Into Research Agreement With Chiesi Farmaceutici 31
Eddingpharm Forms Joint Venture With Chiesi Farmaceutici 32
Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 33
Licensing Agreements 34
Chiesi Farmaceutici Expands Licensing Agreement with Protalix 34
Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 36
Palladio Biosciences Enters into Agreement with Chiesi USA 37
Aratana Therapeutics Enters into Licensing Agreement with Atopix Therapeutics for CRTH2 38
Cornerstone Therapeutics Enters Into Licensing Agreement With Chiesi Farmaceutici For Bethkis 39
CereSpir Enters Into Licensing Agreement With Chiesi Farmaceutici For CHF 5074 40
Cornerstone Enters Into Licensing Agreement With Digestive Care For Pertzye 41
Asset Transactions 42
Laboratorio Reig Jofre Acquires Right for Heparin Sodium in Spain from Chiesi Espana 42
Neos Therapeutics Acquires Tussionex from Chiesi and Coating Place 43
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 44
Acquisition 45
Chiesi Farmaceutici Acquires Atopix Therapeutics for USD79 Million 45
Chiesi Farmaceutici Completes Acquisition Of Remaining 42% Stake In Cornerstone Therapeutics For US$255 Million 46
Chiesi Farmaceutici Acquires Zymenex from Sunstone Capital 48
Cornerstone Therapeutics Completes Acquisition Of EKR Therapeutics For Up To US$150 Million 49
Cornerstone Therapeutics Acquires Pharma Company, Cardiokine 51
Chiesi Farmaceutici SpA – Key Competitors 52
Chiesi Farmaceutici SpA – Key Employees 53
Chiesi Farmaceutici SpA – Locations And Subsidiaries 54
Head Office 54
Other Locations & Subsidiaries 54
Recent Developments 57
Product News 57
11/20/2017: Protalix BioTherapeutics Announces Presentation to be made at the New Horizons in Fabry Disease Conference 57
11/13/2017: Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union 58
09/07/2017: TRIBUTE study shows superiority of Chiesi’s Trimbow (Beclometasone dipropionate (BDP), Formoterol fumarate (FF) and Glycopyrronium (GB)) over Ultibro (indacaterol/glycopyrronium) in reducing COPD exacerbations 59
06/01/2017: Protalix BioTherapeutics Announces FDA Approval to Operate its Current Facility as a Multi-Product Facility 60
05/29/2018: Chiesi Group has presented data at two international congresses on the role of its extrafine formulation ICS/LABA/LAMA vs LABA/LAMA in the treatment of COPD patients 61
05/20/2017: Trimbow is the first triple combination in a single inhaler for the treatment of COPD to receive positive opinion from the CHMP in Europe 63
05/09/2017: Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease 64
04/04/2017: For the second time, Chiesi’s extrafine fixed dose ICS/LABA/LAMA triple therapy earns a place in the pages of The Lancet, with the publication of Chiesi’s TRINITY study 65
02/13/2017: Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium 2017 67
01/29/2018: Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium 2018 68
Product Approvals 69
Jun 12, 2018: Chiesi and Holostem Announce FDA Orphan Drug Designation for GPLSCD01 for treatment of Limbal Stem Cell Deficiency (LSCD) 69
Jan 31, 2018: Protalix BioTherapeutics’ pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration 70
Dec 27, 2017: Protalix BioTherapeutics’ PRX-102 Granted Orphan Drug Designation by the European Commission 71
Oct 09, 2017: Trimbow is accepted for restricted use within NHS Scotland 72
Aug 24, 2017: NICE recommends Holoclar (ex vivo expanded autologous human corneal epithelial cells containing stem cells) for the treatment of moderate to severe limbal stem cell deficiency after eye burns 73
Jul 24, 2017: Chiesi Group receives the European Marketing Authorisation for Trimbow (inhaled corticosteroid / long-acting ß2-agonist / long-acting muscarinic antagonist) 74
Clinical Trials 75
May 25, 2018: Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress 75
Nov 27, 2017: Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference 76
Aug 30, 2017: Inhalation Sciences: PreciseInhale achieves positive results in Chiesi tests 77
Apr 18, 2017: Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies 78
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Chiesi Farmaceutici SpA, Deals By Therapy Area, 2012 to YTD 2018 9
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Horizon Pharma Sells PROCYSBI and QUINSAIR to Chiesi Farmaceutici 14
Chiesi Farmaceutici Acquires Cardiovascular Assets of The Medicines Company for up to USD743.8 Million 15
Atopix Acquires OC459 and CRTH2 Antagonists from Oxagen 17
Atopix Therapeutics Raises Additional Funds through Venture Financing 19
Atopix Therapeutics Raises Funds through Extended Series A Financing 20
Atopix Raises USD5.7 Million in Series A Financing Round 21
Charterhouse Capital Partners Acquires Doc Generici For US$424 Million 22
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 24
Charles River Laboratories International Expands its Agreement with Chiesi Farmaceutici 25
Aptuit Enters into Agreement with Chiesi Farmaceutici 26
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici 27
Pharmaxis Enters into Distribution Agreement with Chiesi Farmaceutici for Bronchitol in US 28
Chiesi Farmaceutici Enters into Agreement With University College London 29
Pharmathen Enters Into Co-Promotion Agreement With Chiesi For Nebulized Inhaled Corticosteroid 30
Activaero Enters Into Research Agreement With Chiesi Farmaceutici 31
Eddingpharm Forms Joint Venture With Chiesi Farmaceutici 32
Veloxis Pharma Enters Into Distribution Agreement With Chiesi Farmaceutici For LCP-Tacro 33
Chiesi Farmaceutici Expands Licensing Agreement with Protalix 34
Chiesi Farmaceutici Enters into Licensing Agreement with Veloxis Pharma 36
Palladio Biosciences Enters into Agreement with Chiesi USA 37
Aratana Therapeutics Enters into Licensing Agreement with Atopix Therapeutics for CRTH2 38
Cornerstone Therapeutics Enters Into Licensing Agreement With Chiesi Farmaceutici For Bethkis 39
CereSpir Enters Into Licensing Agreement With Chiesi Farmaceutici For CHF 5074 40
Cornerstone Enters Into Licensing Agreement With Digestive Care For Pertzye 41
Laboratorio Reig Jofre Acquires Right for Heparin Sodium in Spain from Chiesi Espana 42
Neos Therapeutics Acquires Tussionex from Chiesi and Coating Place 43
Merus Labs International Acquires North America Rights Of FACTIVE Tablets From Cornerstone Therapeutics 44
Chiesi Farmaceutici Acquires Atopix Therapeutics for USD79 Million 45
Chiesi Farmaceutici Completes Acquisition Of Remaining 42% Stake In Cornerstone Therapeutics For US$255 Million 46
Chiesi Farmaceutici Acquires Zymenex from Sunstone Capital 48
Cornerstone Therapeutics Completes Acquisition Of EKR Therapeutics For Up To US$150 Million 49
Cornerstone Therapeutics Acquires Pharma Company, Cardiokine 51
Chiesi Farmaceutici SpA, Key Competitors 52
Chiesi Farmaceutici SpA, Key Employees 53
Chiesi Farmaceutici SpA, Subsidiaries 54
List of Figures
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Chiesi Farmaceutici SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9